A comparative study of the IMMULITE and Enzyme Linked Immuno Sorbent Assay for measuring Tumor Marker CA-125 in Ovarian Cancer Patients in Khyber Pakhtunkhwa
Paper Details
A comparative study of the IMMULITE and Enzyme Linked Immuno Sorbent Assay for measuring Tumor Marker CA-125 in Ovarian Cancer Patients in Khyber Pakhtunkhwa
Abstract
Different assays are used for screening and diagnosis of carcinoma worldwide. Here in Pakistan too, various techniques are used to screen cancers of different organs. Earlier the trend was to use ELISA assay for screening of ovarian cancer but nowadays special CHEMOLUMINESCENT assays are used to screen ovarian cancer. The objective of the study was to examine and compare the results of tumor marker CA-125, evaluated by CHEMOLUMINESCENT assays based (IMMULITE) and ELISA technique. Total of 80 patients having ovarian carcinoma and six healthy persons as control were included in this study. The study population included benign as well as malignant cases of ovarian carcinoma. The level of CA-125 was determined by ELISA and IMMULITE. Analysis of IMMULITE OM.MA assay showed 64 patients (80%) positive for cancer and in 16 patients (20%), the cancer marker was not detected. Analysis of the ELISA results showed 57 patients (72%) positive for cancer and in 23 patients (28%), the cancer antigen was not detected. Six healthy females as control group, showed very low concentration of CA-125. Pearson correlation coefficient (PCC) is 0.358, indicating a direct relation between the two assays values. Paired t-test data of 0.46 gave us an insignificant difference value between both assays. Although there is very small variation in sensitivity and specificity of both the assays but there is significant correlation between ELISA and IMMULITE assays. Hence ELISA can be used to determine CA-125 level in ovarian cancer patients where the IMMULITE assay is not available or is not affordable.
Ahmad B, Nawaz S, Ali S, Bashir S, Mehmood N, Gul B. 2015. Level and Evaluation of Tumor Marker CA-125 in Ovarian Cancer Patients, in Khyber Pakhtun khwa. Asian Pac J Cancer Prev 1, 185-189.
Chauhan SC, Kumar D, Jaggi M. 2007. Mucins in ovarian cancer diagnosis and therapy. Journal of Ovarian Research 2-21.
Eagle K, Ledermann JA. 1997. Tumor Markers in Ovarian Malignancies. The Oncologist 2, 324-329.
Gebauer G. 1999. IMMULITE OM_MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors. Anti-cancer res. 19, 2535-2560.
Hiss D. 2011. Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways. Journal of Oncology 2012, p 23.
Hefler LA, Rosen AC, Graf A H, Lahousen M, Klein M, Leodolter S, Reinthaller A, Kainz C, Tempfer CB. 2000. The Clinical Value of Serum Concentrations of Cancer Antigen 125 in Patients with Primary Fallopian Tube Carcinoma. Cancer 89, 1555-1560.
Jankovic M, Tapuskovic B. 2005. Molecular forms and micro-heterogeneity of the oligosaccharide chain of pregnancy- associated antigen. Human Reproduction 20, 2632-2638.
Jiang W, Huang R, Duan C, Fu, L, Xi Y, Yang, Y, Huang, RP. 2013. Identification of five serum protein markers for detection of ovarian cancer by antibody arrays. PloS one 8(10), e76795. http://dx.doi.org/10.1371/journal.pone.0076795.
Markman M. 1997. The Role of CA-125 in the Management of Ovarian Cancer. The Oncologist 2, 6-9.
Mor G, Visintin I, Lai Y, Zao H, Schwartz P, Rutherford T, Ward DC. 2005. Serum protein markers for early detection of ovarian cancer. Medical Science 102, 7677-7682.
Moss EL, Hollingworth J, Reynolds TM. 2013. The role of CA-125 in Clinical Practices., Journalof Clinical Pathology 2005, 58, 308-312.
Pitta D, Sarian LO, Barreta A, Campos EA, de Angelo Andrade LL, Fachini AM, Derchain S. 2013. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses. BMC Cancer, 13, p 423.
Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. 2001. Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels. Journal of Clinical Oncology 19, 4054-4057.
Robert C, Bast. 2003. Status of Tumor Markers in Ovarian Cancer Screening. Journal of Clinical Oncology. 21, 200-205.
Sarwar S, Siddiqui N, Khokhar RA. 2006. Epithelial Ovarian Cancer at a Cancer Hospital in a Developing Country. Asian Pacific Journal of Cancer Prevention 7, 595-598.
Scholler N, Urban N. 2007. CA-125 in Ovarian Cancer. Biomarkers in Medicine, 1, 513-523.
Thomas CM, Massuger LF, Segers MF, Schijf CP, Doesburg WH, Wobbes T. 1995. Analytical and Clinical Performance of Improved Abbott lMx CA 125 Assay: Comparison with Abbott CA 125 Ria. Clinical Chemistry 41, 211-216.
Vuento MH, Stenman UH, Pirhonen JP, Mäkinen JI, Laippala PJ, Salmi TA. 1997. Significance of a single Ca-125 Assay combined with ultrasound in the early detection of ovarian cancer and Eendometrial cancer. Gynecologic oncology 64, 141-146.
Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Azori M. 2008. Diagnostic Marker for Early Detection of Ovarian Cancer, Clinical Cancer Research 14, 1065-1072.
Xing F, Sui H, Wu Y, Wang Y, Wang D, Zhou SF. 2011. Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. Medical Science Monitor 17, 618-625.
Yin BWT, Lloyd KO. 2001. Molecular cloning of the CA_125 Ovarian Cancer Antigen: Identification AS A NEW MUCIN, MUC1. Journal of Biological and chemical Chronicles 276, 27371-27375.
Zou L, He X, Zhang JW. 2010. The efficacy of YKL-40 and CA-125 as biomarkers for Ephithelial Ovarian Cancer. Brazilian Journal of Medical and Biological Research 12, 1232-1238.
Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, Zhong XY. 2010. Proteomics and Biomarkers for Ovarian Cancer Diagnosis. Annals of Clinical & Laboratory Science, 40, 218-225.
Seema Nawaz, Bashir Ahmad, Saeed Ahmad, Saad Ahmad Khan, Sajid Ali, 2020. A comparative study of the IMMULITE and Enzyme Linked Immuno Sorbent Assay for measuring Tumor Marker CA-125 in Ovarian Cancer Patients in Khyber Pakhtunkhwa. Int. J. Biosci., 16(3), 242-252.
Copyright © 2020 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.